Genetic variability of CYP2D6, CYP2C19, and CYP1A2 in patients with treatment resistance to antipsychotics and antidepressants
Year: 2025
Type: article
Study design: Observational Study
Abstract: Aim: The study objective was to assess the frequency of gene alleles responsible for the metabolism and elimination of drugs in treatment-resistant patients to antipsychotics and/or antidepressants. Materials and methods: The frequency of CYP2D6, CYP2C19, and CYP1A2 gene alleles was studied in 133 patients aged 18–70 years in comparison with a healthy population. Results: Patients with treatment resistance to antipsychotics and/or antidepressants demonstrated the increased allele frequency of CYP2D6 *3 (4.5% vs. 1.0%, OR 4.5, p=0.003), CYP2C19 *17 (24.4% vs. 15.4%, OR 1.78, p=0.027), CYP1A2 *1A (68.5% vs. 41.4%, OR 3.03, p<0.001), decreased allele frequency of CYP2C19 *1 (61.3% vs. 88.3%, OR 0.21, p<0.001) and CYP1A2 *1F (30.4% vs. 58.6%, p<0.001). The frequency of CYP2D6 *5 allele was higher in females (3.8% vs. 0% in males, OR 11.6, p=0.029). No age difference was found in CYP2D6, CYP2C19, and CYP1A2 alleles frequencies in the subgroups of patients aged 18–30 years versus 31–70 years. Conclusion: The observed difference in the genotype prevalence of CYP2D6, CYP2C19, and CYP1A2 in patients with antipsychotic and/or antidepressant resistance allows us to recommend pharmacogenetic testing for routine clinical practice in order to select the most effective and safe treatment for patients with antipsychotic and antidepressant resistance.
Source: Folia Medica
Authors: Tatiana A. Zhiganova, Evgenia A. Radkova
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W4413826863